To understand the prospects for human papillomavirus (HPV) mass vaccination in the setting of a developing country, we studied the co-occurrence of seropositivity to multiple high-risk (hr) HPV types among HIV-positive and HIV-negative Ugandan women. Our seroepidemiological study was conducted among 2053 women attending antenatal clinics. Sera were analysed for antibodies to eight hrHPV types of the α-7 (18/45) and α-9 (16/31/33/35/52/58) species of HPV by using a multiplex serology assay. Our results show that seropositivity for greater than one hrHPV type was as common (18 %) as for a single type (18 %). HIV-positive women had higher HPV16, HPV18 and HPV45 seroprevalences than HIV-negative women. In multivariate logistic regression analysis, age (>30 years) and level of education (secondary school and above) reduced the risk, whereas parity (>5) and HIV-positivity increased the risk for multiple hrHPV seropositivity. However, in stepwise logistic regression analyses, HIV-status remained the only independent, stand-alone risk factor [odds ratio (OR) 1.7, 95 % confidence interval (CI) 1.0–2.8). On the other hand, the risk of HPV16 or HPV18 seropositive women, as compared to HPV16 or HPV18 seronegative women, for being seropositive to other hrHPV types was not significantly different when they were grouped by HIV-status (ORHPV16/HIV+ 12, 95 % CI 4.5–32 versus ORHPV16/HIV− 22, 95 % CI 15–31 and ORHPV18/HIV+ 58, 95 % CI 14–242 versus ORHPV18/HIV− 45, 95 % CI 31–65). In conclusion, seropositivity to HPV16, HPV18 and to non-vaccine hrHPV types is common in Ugandan women, suggesting that there is little natural cross-protective immunity between the types. HIV-positivity was an independent, stand-alone, albeit moderate risk factor for multiple hrHPV seropositivity. HPV mass vaccination may be the most appropriate method in the fight against cervical cancer in the Ugandan population.
af GeijersstamV.,
KiburM.,
WangZ.,
KoskelaP.,
PukkalaE.,
SchillerJ.,
LehtinenM.,
DillnerJ.1998; Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177:1710–1714 [View Article][PubMed]
AultK. A.Future II Study Group2007; Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868[CrossRef]
BanuraC.,
FranceschiS.,
van DoornL. J.,
ArslanA.,
KleterB.,
Wabwire-MangenF.,
MbiddeE. K.,
QuintW.,
WeiderpassE.2008a; Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 123:2180–2187 [View Article][PubMed]
BanuraC.,
FranceschiS.,
DoornL. J.,
ArslanA.,
Wabwire-MangenF.,
MbiddeE. K.,
QuintW.,
WeiderpassE.2008b; Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 197:555–562 [View Article][PubMed]
BanuraC.,
SandinS.,
van DoornL. J.,
QuintW.,
KleterB.,
Wabwire-MangenF.,
MbiddeE. K.,
WeiderpassE.2010; Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect Agent Cancer 5:7 [View Article][PubMed]
BlossomD. B.,
BeigiR. H.,
FarrellJ. J.,
MackayW.,
QadadriB.,
BrownD. R.,
RwambuyaS.,
WalkerC. J.,
KambuguF. S. et al.other authors2007; Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 79:758–765 [View Article][PubMed]
BrownD. R.,
KjaerS. K.,
SigurdssonK.,
IversenO. E.,
Hernandez-AvilaM.,
WheelerC. M.,
PerezG.,
KoutskyL. A.,
TayE. H. et al.other authors2009; The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199:926–935 [View Article][PubMed]
CliffordG. M.,
GonçalvesM. A.,
FranceschiS.HPV and HIV Study Group2006; Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20:2337–2344 [View Article][PubMed]
CliffordG. M.,
ShinH. R.,
OhJ. K.,
WaterboerT.,
JuY. H.,
VaccarellaS.,
QuintW.,
PawlitaM.,
FranceschiS.2007; Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16:1874–1879 [View Article][PubMed]
De VuystH.,
LilloF.,
BroutetN.,
SmithJ. S.2008; HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17:545–554 [View Article][PubMed]
DillnerJ.,
KallingsI.,
BrihmerC.,
SikströmB.,
KoskelaP.,
LehtinenM.,
SchillerJ. T.,
SappM.,
MårdhP. A.1996; Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173:1394–1398 [View Article][PubMed]
DondogB.,
CliffordG. M.,
VaccarellaS.,
WaterboerT.,
UnurjargalD.,
AvirmedD.,
EnkhtuyaS.,
KommossF.,
WentzensenN. et al.other authors2008; Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 17:1731–1738 [View Article][PubMed]
HoG. Y.,
StudentsovY.,
HallC. B.,
BiermanR.,
BeardsleyL.,
LempaM.,
BurkR. D.2002; Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186:737–742 [View Article][PubMed]
HoG. Y.,
StudentsovY. Y.,
BiermanR.,
BurkR. D.2004; Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13:110–116 [View Article][PubMed]
KaasilaM.,
KoskelaP.,
KirnbauerR.,
PukkalaE.,
SurcelH.-M.,
LehtinenM.2009; Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 125:2166–2172 [View Article][PubMed]
KatahoireR. A.,
JittaJ.,
KivumbiG.,
MurokoraD.,
ArubeW. J.,
SiuG.,
ArinaitweL.,
BinghamA.,
MugishaE. et al.other authors2008; An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr J Reprod Health 12:159–172[PubMed]
KizitoD.,
WoodburnP. W.,
KesandeB.,
AmekeC.,
NabulimeJ.,
MuwangaM.,
GrosskurthH.,
ElliottA. M.2008; Uptake of HIV and syphilis testing of pregnant women and their male partners in a programme for prevention of mother-to-child HIV transmission in Uganda. Trop Med Int Health 13:680–682 [View Article][PubMed]
KjellbergL.,
WangZ.,
WiklundF.,
EdlundK.,
AngströmT.,
LennerP.,
SjöbergI.,
HallmansG.,
WallinK. L. et al.other authors1999; Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 80:391–398[PubMed]
MerikukkaM.,
KaasilaM.,
NamujjuP. B.,
PalmrothJ.,
KirnbauerR.,
PaavonenJ.,
SurcelH. M.,
LehtinenM.2011; Differences in incidence and co-occurrence of vaccine and non-vaccine human papillomavirus (HPV) types in Finnish population before HPV mass vaccination suggest competitive advantage for HPV33. Int J Cancer 128:1114–1119 [View Article][PubMed]
MolanoM.,
Van den BruleA.,
PlummerM.,
WeiderpassE.,
PossoH.,
ArslanA.,
MeijerC. J.,
MuñozN.,
FranceschiS.HPV Study Group2003; Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158:486–494 [View Article][PubMed]
MoscickiA. B.,
EllenbergJ. H.,
FarhatS.,
XuJ.2004; Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 190:37–45 [View Article][PubMed]
MpairweH.,
MuhangiL.,
NamujjuP. B.,
KisituA.,
TumusiimeA.,
MuwangaM.,
WhitworthJ. A.,
OnyangoS.,
BiryahwahoB.,
ElliottA. M.2005; HIV risk perception and prevalence in a program for prevention of mother-to-child HIV transmission: comparison of women who accept voluntary counseling and testing and those tested anonymously. J Acquir Immune Defic Syndr 39:354–358 [View Article][PubMed]
NamujjuP. B.,
SurcelH.-M.,
KirnbauerR.,
KaasilaM.,
BanuraC.,
ByaruhangaR.,
MuwangaM.,
MbiddeE. K.,
KoskelaP.,
LehtinenM.2010; Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Scand J Infect Dis 42:522–526 [View Article][PubMed]
NamujjuP. B.,
HedmanL.,
HedmanK.,
BanuraC.,
MbiddeE. K.,
KizitoD.,
ByaruhangaR. N.,
MuwangaM.,
KirnbauerR. et al.other authors2011; Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. BMC Res Notes 4:170 [View Article][PubMed]
OdidaM.,
de SanjoséS.,
QuintW.,
BoschX. F.,
KlaustermeierJ.,
WeiderpassE.2008; Human papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 8:85 [View Article][PubMed]
PaavonenJ.,
NaudP.,
SalmerónJ.,
WheelerC. M.,
ChowS. N.,
ApterD.,
KitchenerH.,
CastellsagueX.,
TeixeiraJ. C. et al.other authors2009; Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314 [View Article][PubMed]
PalmrothJ.,
NamujjuP.,
Simen-KapeuA.,
KatajaV.,
SurcelH.-M.,
TuppurainenM.,
YliskoskiM.,
SyrjänenK.,
LehtinenM.2010; Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis 42:379–384 [View Article][PubMed]
SafaeianM.,
KiddugavuM.,
GravittP. E.,
GangeS. J.,
SsekasanvuJ.,
MurokoraD.,
SklarM.,
SerwaddaD.,
WawerM. J. et al.other authors2008; Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev 17:1300–1307 [View Article][PubMed]
SerwaddaD.,
WawerM. J.,
ShahK. V.,
SewankamboN. K.,
DanielR.,
LiC.,
LorinczA.,
MeehanM. P.,
Wabwire-MangenF.,
GrayR. H.1999; Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 180:1316–1319 [View Article][PubMed]
SlaymakerE.,
BwanikaJ. B.,
KasambaI.,
LutaloT.,
MaherD.,
ToddJ.2009; Trends in age at first sex in Uganda: evidence from Demographic and Health Survey data and longitudinal cohorts in Masaka and Rakai. Sex Transm Infect 85:Suppl. 1i12–i19 [View Article][PubMed]
Soto-De LeonS.,
CamargoM.,
SanchezR.,
MunozM.,
Perez-PradosA.,
PurroyA.,
PatarroyoM. E.,
PatarroyoM. A.2011; Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS ONE 6:e14705 [View Article][PubMed]
SyrjänenS.,
WaterboerT.,
SarkolaM.,
MichaelK.,
RintalaM.,
SyrjänenK.,
GrenmanS.,
PawlitaM.2009; Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 90:1515–1526 [View Article][PubMed]
WaterboerT.,
SehrP.,
MichaelK. M.,
FranceschiS.,
NielandJ. D.,
JoosT. O.,
TemplinM. F.,
PawlitaM.2005; Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 51:1845–1853 [View Article][PubMed]
WoodmanC. B.,
CollinsS.,
WinterH.,
BaileyA.,
EllisJ.,
PriorP.,
YatesM.,
RollasonT. P.,
YoungL. S.2001; Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357:1831–1836 [View Article][PubMed]